ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome
Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.
Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations
Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.
Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Magrolimab plus Azacitidine for Myelodysplastic Syndrome
Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.
The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment
Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.
The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome
Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.
Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome
Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.
Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome
Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.
Treatment Goals for Patients with Myelodysplastic Syndrome
Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.
Risk Stratification for Patients with Myelodysplastic Syndrome
Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.
The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)
Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.
An Overview of Myelodysplastic Syndrome (MDS)
Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.
Unmet Needs and the Future of AML Treatment
Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.
The Importance of Bone Marrow Biopsies in AML Patients on Venetoclax Treatment
Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.
Management of Cytopenia in Patients on Venetoclax + Azacitidine Therapy
Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.
Case Presentation: An 81-Year-Old Male with AML
Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.
Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.
Treatment Options for AML Patients with IDH2, RUNX1, or DNMT3A Mutations
Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.
Treatment Options for Secondary AML
Eytan Stein, MD, reviews the available treatment options for patients with secondary AML or AML with myelodysplasia-related changes.
Intensive Induction Therapy In AML
Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction therapy.
Frontline Treatment Options for Patients with AML
Eytan Stein, MD, provides an overview of the frontline treatment options currently available for acute myeloid leukemia.
The Goals of Treatment in AML
Experts explain the goals of treatment for acute myeloid leukemia and the challenges presented.
Diagnosis and Cytogenetic Testing in AML
Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.
Overview of Acute Myeloid Leukemia (AML)
Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.
2 Clarke Drive Cranbury, NJ 08512